Kymera Therapeutics
Tracked across 1 events · 6 articles · First seen Apr 13, 2026 · Last active Jun 08, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: Kymera Therapeutics received Fast Track designation from the United States — Food and Drug Administration for its drug KT-621, which is expected to accelerate its development and potential approval for treating asthma.
Apr 13, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Kymera Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard